Efficacy of Offering a Self-sampling Device by the GP to Reach Underscreened Women

The ESSAG trial invests the impact of offering a free self-sampling device (SSD) on the cervical cancer screening rate of underscreened women. This study is aimed at women between the age of 31 and 65 who did not have a smear taken during the last 6 years. In order to assess the effect of a) providing the SSD, and b) the intervention of the general practitioner (GP) (either face-to-face, either by sending the SSD by letter), a randomized control trial is set up with three arms. The ESSAG trial evolves from a collaboration between Universiteit Gent and Vrije Universiteit Brussel, Katholieke Universiteit Leuven, Universiteit Antwerpen, Sciensano, het Centrum voor Kankeropsporing en het Belgisch Kankerregister, and is funded by "Kom Op Tegen Kanker".

Inclusion Criteria:women between 31-64 years oldliving in Flanderseligible for the Flemish actions with regard to population screeningwithout a smear registered in the Belgian Cancer Registry in the last 6 yearsregistered as GMD patient in one of the participating GP practicesExclusion Criteria:hysterectomypregnancy(past) diagnosis of cervical cancer